跳至主要内容
临床试验/NCT03887520
NCT03887520已完成不适用

Multi-center Cross-sectional Epidemiological Study to Characterize the Prevalence and Distribution of Lipoprotein(a) Levels Among Patients With Established Cardiovascular Disease

Novartis Pharmaceuticals897 个研究点 分布在 2 个国家目标入组 49,001 人开始时间: 2018年11月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
49,001
试验地点
897
主要终点
Percentage of patients with normal and elevated Lipoprotein(a) (Lp(a)) levels in patients with established Cardiovascular Disease (CVD)

研究概览

简要总结

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Established CVD defined as one of the following:
  • History of a myocardial infarction (MI) ≥3 months and ≤10 years before the study visit
  • History of ischemic stroke ≥ 3 months and ≤ 10 years before the study visit
  • Symptomatic PAD (intermitted claudication with ankle-brachial index ≤0.90 and/or lower limb amputation or re-vascularization due to lower limb ischemia

排除标准

  • Patients currently enrolled in clinical studies with investigational drugs

结局指标

主要结局

Percentage of patients with normal and elevated Lipoprotein(a) (Lp(a)) levels in patients with established Cardiovascular Disease (CVD)

时间窗: At screening

Prevalence of normal and elevated Lp(a) levels in patients with established CVD

次要结局

  • Low-density lipoprotein cholesterol (LDL(C)) values (corrected and uncorrected)(At screening)
  • Lp(a) values by region and country(At screening)
  • Lipoprotein(a) (Lp(a)) values(At screening)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (897)

Loading locations...

相似试验